X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
https://pharmatimes.com/news/us-study-suggests-bms-cancer-drug-could-target-parkinsons-causing-protein/
https://www.globenewswire.com/news-release/2024/06/06/2894545/0/en/Replimune-Announces-Positive-Topline-Primary-Analysis-Data-by-Independent-Central-Review-from-IGNYTE-Clinical-Trial-of-RP1-plus-Nivolumab-in-Anti-PD1-Failed-Melanoma.html
https://www.pharmaceutical-technology.com/news/i-mab-bms-gastric-cancers/
https://www.fiercepharma.com/pharma/asco-opdivo-yervoy-combo-bristol-myers-calls-roches-and-astrazenecas-bets-first-line-liver
https://www.reuters.com/business/healthcare-pharmaceuticals/pre-surgery-treatment-with-bristol-myers-combination-therapy-leads-better-skin-2024-06-02/
https://www.pharmaceutical-technology.com/news/bms-secures-another-ec-approval-for-opdivo-combination/
https://www.fiercepharma.com/pharma/asco-bristol-myers-i-o-triplet-iovance-touts-paradigm-changing-amtagvi-keytruda-melanoma
https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Updated-Action-Date-by-the-U.S.-Food-and-Drug-Administration-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx
https://xbrane.com/en/mfn_news/xbrane-successfully-scales-up-xdivane-biosimilar-candidate-to-opdivo-and-run-an-active-partnering-process/
https://www.prnewswire.com/news-releases/halozyme-announces-bristol-myers-squibb-received-updated-action-date-from-the-us-food-and-drug-administration-for-subcutaneous-nivolumab-co-formulated-with-enhanze-302150881.html
https://www.fiercepharma.com/pharma/bristol-myers-chalks-failure-astrazenecas-imfinzi-stays-king-stage-3-lung-cancer#:~:text=The%20latest%20failure%20comes%20from,3%20NSCLC%2C%20BMS%20said%20Friday.
https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-Application-for-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase/default.aspx
https://news.bms.com/news/corporate-financial/2024/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-for-the-First-Line-Treatment-of-Adult-Patients-with-Microsatellite/default.aspx
https://www.biopharmadive.com/news/bristol-myers-layoffs-restructuring-cost-savings/714254/
https://www.fiercebiotech.com/biotech/ultimovacs-lays-40-survive-wake-cancer-vaccines-phase-2-fail
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-liver-cancer-treatment-meets-main-goal-late-stage-study-2024-03-20/
https://www.globenewswire.com//news-release/2024/03/07/2841921/0/en/Ultimovacs-Announces-Topline-Results-from-INITIUM-Study-Evaluating-UV1-Vaccination-Added-to-Ipilimumab-and-Nivolumab-in-Patients-with-Unresectable-or-Metastatic-Malignant-Melanoma.html
https://www.fiercepharma.com/pharma/bristol-myers-unfolds-subcutaneous-opdivo-data-kidney-cancer-i-o-battle-heads-new-front
https://www.globenewswire.com//news-release/2023/12/27/2801365/0/en/SELLAS-Life-Sciences-Reports-Positive-Follow-Up-Immune-Response-and-Survival-Data-in-Completed-Phase-1-Study-of-Galinpepimut-S-Combined-with-Opdivo-in-Advanced-Malignant-Pleural-Me.html
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-opdualag-hits-wall-colorectal-cancer-scrapped-trial
https://www.fiercepharma.com/pharma/seagen-adcetris-and-bristol-opdivo-boost-hopes-another-adc-pd-1-combo
https://www.fiercepharma.com/pharma/bms-shows-success-opdivo-yervoy-combo-first-line-colorectal-cancer
https://www.asiaone.com/business/first-patient-enrolled-phase-iii-clinical-trial-boan-biotechs-nivolumab-injection
https://news.bms.com/news/corporate-financial/2023/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx
https://www.fiercepharma.com/pharma/bristol-myers-opdivo-chalks-bladder-cancer-win-padcev-keytruda-casts-long-shadow
https://news.bms.com/news/corporate-financial/2023/Phase-3-CheckMate--67T-Trial-of-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase-Meets-Co-Primary-Endpoints-in-Advanced-or-Metastatic-Clear-Cell-Renal-Cell-Carcinoma/default.aspx
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-opdivo-reign-expands-new-earlier-stage-melanoma-nod
https://www.onclive.com/view/fda-approves-adjuvant-nivolumab-for-completely-resected-stage-iib-c-melanoma
https://endpts.com/amgen-readies-phiii-trial-for-first-opdivo-biosimilar-with-launch-unlikely-before-2028/
https://www.onclive.com/view/neoadjuvant-nivolumab-ipilimumab-combo-elicits-responses-safety-in-resectable-hcc
https://www.onclive.com/view/biomarker-analysis-contextualizes-rfs-benefit-with-nivolumab-in-metastatic-melanoma
Market Place
Share 
